In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3003-3009

  Andes, D ^a   Craig, W ^a   Nielsen, L A ^b   Kristensen, H H ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NOVOZYMES A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NZ 2114; PLECTASIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GRAM POSITIVE BACTERIUM; INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 67649910494     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01584-08     Document Type: Article

References (17)

1. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
2. Ambrose, P. G., J. B. Anon, S. M. Bhavnani, O. O. Okusanya, R. N. Jones, M. R. Paglia, J. Kahn, and G. L. Drusano. 2008. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagn. Microbiol. Infect. Dis. 61:13-20.
3. Andes, D., and W. A. Craig. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
4. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
5. Craig, W. A. 1998. Pharmacokinetics and pharmacodynamics of antibiotics in mice and men. Clin. Infect. Dis. 26:1-12.
6. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, MD.
7. Craig, W. A., and B. Suh. 1996. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-402. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams and Wilkins Co., Baltimore, MD.
8. Craig, W. A., and D. R. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
9. Craig, W. A., and P. G. Welling. 1977. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 2:252-268.
10. Drusano, G. L., S. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II-III dose for everninomycin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
11. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calamae, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relationships at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
12. Mygind, P. H., R. L. Fischer, K. M. Schnorr, M. T. Hansen, C. P. Sönksen, S. Ludvigsen, D. Raventós, S. Buskov, B. Christensen, L. De Maria, O. Taboureau, D. Yaver, S. G. Elvig-Jørgensen, M. V. Sørensen, B. E. Christensen, S. Kjaerulff, N. Frimodt-Moller, R. I. Lehrer, M. Zasloff, and H. H. Kristensen. 2005. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437:975-980.
13. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
14. NCCLS. 2000. Performance standards for antimicrobial disk 1 susceptibility tests. Approved standard M2-A7, 7th ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
15. Sandvang, D., P. H. Mygind, M. E. Jones, D. F. Sahm, and H. Kristensen. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-1663, p. 243.
16. Talbot, G. H., J. Bradley, J. E. Edwards Jr., D. Gilbert, M. Scheld, and J. G. Bartlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
17. Zuluaga, A. F., B. E. Salazar, C. A. Rodriguez, A. X. Zapata, M. Agudelo, and O. Vesga. 2006. Neutropenia induced in outbred mice by a simplified lowdose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.